Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer

Shingo Harita, Youichi Watanabe, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Shoichi Kuyama, Toshiyuki Kozuki, Haruhito Kamei, Atsuhiko Tada, Niro Okimoto, Kenichi Genba, Shinichi Tada, Hiroshi Ueoka, Shunkichi Hiraki, Mitsune Tanimoto

Research output: Contribution to journalArticle

Abstract

Background: A phase II study of a triplet chemotherapy with the administration sequence of gemcitabine (GEM), docetaxel (DCT) and cisplatin (CDDP) (OLCSG9908) was previously conducted in patients with advanced non-small cell lung cancer (NSCLC). The objective response rate was 34% and the median survival time (MST) and 1-year survival rate were 11.7 months and 49%, respectively. In an in vitro study of different sequence exposures to GEM and DCT, it was reported that the synergistic effect was more prominent using the administration sequence of DCT followed by GEM compared with the reverse sequence. In order to estimate the effects of the administration sequence, a phase II study of the same triplet chemotherapy was conducted with the administration sequence of DCT, CDDP and GEM. Patients and Methods: Patients with unresectable stage IIIB/IV NSCLC were eligible. All drugs were given intravenously on days 1 and 8, and repeated every 4 weeks for up to 4 cycles. DCT (30 mg/m2) was given first, followed by CDDP (40 mg/m 2) and GEM (800 mg/m2). Results: Thirty-four patients were enrolled on this study (OLCSGO101). The objective response rate was 38% (95% CI: 22-56%). As grade 3/4 hematological toxicities, neutropenia, thrombocytopenia and anemia were observed in 70%, 41% and 21%, respectively, and febrile neutropenia was observed in 12%. As grade 3/4 non-hematological toxicities, vomiting and liver dysfunction were observed in 15% and 18%, respectively. These toxicities were manageable by conventional therapy. The MST and 1-year survival rate were 13.3 months (95% CI: 7.8-18.7 months) and 55% (95% CI: 38-73%), respectively. These results were similar to those of OLCSG9908. Conclusion: This triplet chemotherapy is well tolerated and effective in patients with advanced NSCLC, however, the treatment outcome was not significantly influenced by the administration sequence of DCT and GEM.

Original languageEnglish
Pages (from-to)1637-1641
Number of pages5
JournalAnticancer Research
Volume26
Issue number2 B
Publication statusPublished - Mar 2006

Fingerprint

docetaxel
gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Survival Rate
Febrile Neutropenia
Survival
Neutropenia
Thrombocytopenia
Vomiting
Liver Diseases
Anemia

Keywords

  • Administration sequence
  • Cisplatin
  • Docetaxel
  • Gemcitabine
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer. / Harita, Shingo; Watanabe, Youichi; Kiura, Katsuyuki; Tabata, Masahiro; Takigawa, Nagio; Kuyama, Shoichi; Kozuki, Toshiyuki; Kamei, Haruhito; Tada, Atsuhiko; Okimoto, Niro; Genba, Kenichi; Tada, Shinichi; Ueoka, Hiroshi; Hiraki, Shunkichi; Tanimoto, Mitsune.

In: Anticancer Research, Vol. 26, No. 2 B, 03.2006, p. 1637-1641.

Research output: Contribution to journalArticle

Harita, S, Watanabe, Y, Kiura, K, Tabata, M, Takigawa, N, Kuyama, S, Kozuki, T, Kamei, H, Tada, A, Okimoto, N, Genba, K, Tada, S, Ueoka, H, Hiraki, S & Tanimoto, M 2006, 'Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer', Anticancer Research, vol. 26, no. 2 B, pp. 1637-1641.
Harita, Shingo ; Watanabe, Youichi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Takigawa, Nagio ; Kuyama, Shoichi ; Kozuki, Toshiyuki ; Kamei, Haruhito ; Tada, Atsuhiko ; Okimoto, Niro ; Genba, Kenichi ; Tada, Shinichi ; Ueoka, Hiroshi ; Hiraki, Shunkichi ; Tanimoto, Mitsune. / Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer. In: Anticancer Research. 2006 ; Vol. 26, No. 2 B. pp. 1637-1641.
@article{7e8395dbf7c54ee788717ef4b056f321,
title = "Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer",
abstract = "Background: A phase II study of a triplet chemotherapy with the administration sequence of gemcitabine (GEM), docetaxel (DCT) and cisplatin (CDDP) (OLCSG9908) was previously conducted in patients with advanced non-small cell lung cancer (NSCLC). The objective response rate was 34{\%} and the median survival time (MST) and 1-year survival rate were 11.7 months and 49{\%}, respectively. In an in vitro study of different sequence exposures to GEM and DCT, it was reported that the synergistic effect was more prominent using the administration sequence of DCT followed by GEM compared with the reverse sequence. In order to estimate the effects of the administration sequence, a phase II study of the same triplet chemotherapy was conducted with the administration sequence of DCT, CDDP and GEM. Patients and Methods: Patients with unresectable stage IIIB/IV NSCLC were eligible. All drugs were given intravenously on days 1 and 8, and repeated every 4 weeks for up to 4 cycles. DCT (30 mg/m2) was given first, followed by CDDP (40 mg/m 2) and GEM (800 mg/m2). Results: Thirty-four patients were enrolled on this study (OLCSGO101). The objective response rate was 38{\%} (95{\%} CI: 22-56{\%}). As grade 3/4 hematological toxicities, neutropenia, thrombocytopenia and anemia were observed in 70{\%}, 41{\%} and 21{\%}, respectively, and febrile neutropenia was observed in 12{\%}. As grade 3/4 non-hematological toxicities, vomiting and liver dysfunction were observed in 15{\%} and 18{\%}, respectively. These toxicities were manageable by conventional therapy. The MST and 1-year survival rate were 13.3 months (95{\%} CI: 7.8-18.7 months) and 55{\%} (95{\%} CI: 38-73{\%}), respectively. These results were similar to those of OLCSG9908. Conclusion: This triplet chemotherapy is well tolerated and effective in patients with advanced NSCLC, however, the treatment outcome was not significantly influenced by the administration sequence of DCT and GEM.",
keywords = "Administration sequence, Cisplatin, Docetaxel, Gemcitabine, Non-small cell lung cancer",
author = "Shingo Harita and Youichi Watanabe and Katsuyuki Kiura and Masahiro Tabata and Nagio Takigawa and Shoichi Kuyama and Toshiyuki Kozuki and Haruhito Kamei and Atsuhiko Tada and Niro Okimoto and Kenichi Genba and Shinichi Tada and Hiroshi Ueoka and Shunkichi Hiraki and Mitsune Tanimoto",
year = "2006",
month = "3",
language = "English",
volume = "26",
pages = "1637--1641",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer

AU - Harita, Shingo

AU - Watanabe, Youichi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Takigawa, Nagio

AU - Kuyama, Shoichi

AU - Kozuki, Toshiyuki

AU - Kamei, Haruhito

AU - Tada, Atsuhiko

AU - Okimoto, Niro

AU - Genba, Kenichi

AU - Tada, Shinichi

AU - Ueoka, Hiroshi

AU - Hiraki, Shunkichi

AU - Tanimoto, Mitsune

PY - 2006/3

Y1 - 2006/3

N2 - Background: A phase II study of a triplet chemotherapy with the administration sequence of gemcitabine (GEM), docetaxel (DCT) and cisplatin (CDDP) (OLCSG9908) was previously conducted in patients with advanced non-small cell lung cancer (NSCLC). The objective response rate was 34% and the median survival time (MST) and 1-year survival rate were 11.7 months and 49%, respectively. In an in vitro study of different sequence exposures to GEM and DCT, it was reported that the synergistic effect was more prominent using the administration sequence of DCT followed by GEM compared with the reverse sequence. In order to estimate the effects of the administration sequence, a phase II study of the same triplet chemotherapy was conducted with the administration sequence of DCT, CDDP and GEM. Patients and Methods: Patients with unresectable stage IIIB/IV NSCLC were eligible. All drugs were given intravenously on days 1 and 8, and repeated every 4 weeks for up to 4 cycles. DCT (30 mg/m2) was given first, followed by CDDP (40 mg/m 2) and GEM (800 mg/m2). Results: Thirty-four patients were enrolled on this study (OLCSGO101). The objective response rate was 38% (95% CI: 22-56%). As grade 3/4 hematological toxicities, neutropenia, thrombocytopenia and anemia were observed in 70%, 41% and 21%, respectively, and febrile neutropenia was observed in 12%. As grade 3/4 non-hematological toxicities, vomiting and liver dysfunction were observed in 15% and 18%, respectively. These toxicities were manageable by conventional therapy. The MST and 1-year survival rate were 13.3 months (95% CI: 7.8-18.7 months) and 55% (95% CI: 38-73%), respectively. These results were similar to those of OLCSG9908. Conclusion: This triplet chemotherapy is well tolerated and effective in patients with advanced NSCLC, however, the treatment outcome was not significantly influenced by the administration sequence of DCT and GEM.

AB - Background: A phase II study of a triplet chemotherapy with the administration sequence of gemcitabine (GEM), docetaxel (DCT) and cisplatin (CDDP) (OLCSG9908) was previously conducted in patients with advanced non-small cell lung cancer (NSCLC). The objective response rate was 34% and the median survival time (MST) and 1-year survival rate were 11.7 months and 49%, respectively. In an in vitro study of different sequence exposures to GEM and DCT, it was reported that the synergistic effect was more prominent using the administration sequence of DCT followed by GEM compared with the reverse sequence. In order to estimate the effects of the administration sequence, a phase II study of the same triplet chemotherapy was conducted with the administration sequence of DCT, CDDP and GEM. Patients and Methods: Patients with unresectable stage IIIB/IV NSCLC were eligible. All drugs were given intravenously on days 1 and 8, and repeated every 4 weeks for up to 4 cycles. DCT (30 mg/m2) was given first, followed by CDDP (40 mg/m 2) and GEM (800 mg/m2). Results: Thirty-four patients were enrolled on this study (OLCSGO101). The objective response rate was 38% (95% CI: 22-56%). As grade 3/4 hematological toxicities, neutropenia, thrombocytopenia and anemia were observed in 70%, 41% and 21%, respectively, and febrile neutropenia was observed in 12%. As grade 3/4 non-hematological toxicities, vomiting and liver dysfunction were observed in 15% and 18%, respectively. These toxicities were manageable by conventional therapy. The MST and 1-year survival rate were 13.3 months (95% CI: 7.8-18.7 months) and 55% (95% CI: 38-73%), respectively. These results were similar to those of OLCSG9908. Conclusion: This triplet chemotherapy is well tolerated and effective in patients with advanced NSCLC, however, the treatment outcome was not significantly influenced by the administration sequence of DCT and GEM.

KW - Administration sequence

KW - Cisplatin

KW - Docetaxel

KW - Gemcitabine

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=33645830090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645830090&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 1637

EP - 1641

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -